India to Lebanon: Acetylsalicylic Export Trade Route

To import finished pharmaceutical formulations containing acetylsalicylic acid into Lebanon, compliance with the Lebanese Ministry of Public Health (MOPH) regulations is mandatory. The registration process involves submitting a Common Technical Document (CTD) dossier, which includes detailed information on the product's quality, safety, and efficacy. The CTD format is structured into five modules:

1. Administrative and Product Information: Includes application forms, product labeling, and a summary of the dossier.

2. Common Technical Document Summaries: Provides overviews of quality, non-clinical, and clinical data.

3. Quality (Pharmaceutical Documentation): Details on the manufacturing process, control of materials, and product specifications.

4. Non-Clinical Study Reports: Information from pharmacology and toxicology studies.

5. Clinical Study Reports: Data from clinical trials demonstrating the product's efficacy and safety.

The registration process is overseen by the Technical Committee within the MOPH, which evaluates the submitted dossiers. For branded products imported from reference countries, the registration may proceed directly through the Technical Committee without further review from sub-committees. However, for other products, sub-committees may assess specific modules, particularly those related to quality and clinical studies. The final decision is issued by the Minister of Health, granting the market authorization certificate.

Timelines for approval can vary based on the completeness of the submitted dossier and the specific product under review. While exact registration fees are not specified, applicants should anticipate costs associated with dossier preparation, submission, and potential inspections.

Good Manufacturing Practice (GMP) inspections are a critical component of the registration process. Indian manufacturing facilities intending to export to Lebanon must comply with GMP standards as outlined in Schedule M of the Drugs and Cosmetics Act, 1940. The Drugs Controller General of India (DCGI) has mandated that state drug regulators enforce revised GMP standards by January 2026, aligning India's pharmaceutical manufacturing norms with global standards.

Indian exporters of acetylsalicylic acid formulations must adhere to stringent GMP standards to supply products to Lebanon. Compliance with Schedule M of the Drugs and Cosmetics Act, 1940, is essential, encompassing various aspects of manufacturing, including premises, equipment, materials, documentation, production, quality control, validation, personal hygiene, sterile manufacturing, HVAC systems, water systems, packaging, labeling, self-inspection, and contract manufacturing.

The Central Drugs Standard Control Organisation (CDSCO) is progressively upgrading Schedule M to align more closely with WHO GMP and Pharmaceutical Inspection Co-operation Scheme (PIC/S) standards, ensuring global harmonization. Manufacturers must obtain a Manufacturing License (Form 25/28 for non-sterile; Form 28A for sterile) following inspection by CDSCO or state FDA authorities.

As of March 2026, specific details regarding Indian facilities currently approved by the Lebanese National Drug Regulatory Authority (DRA) are not publicly available. Similarly, information on recent inspections or regulatory actions by the National DRA against Indian pharmaceutical companies has not been disclosed.

In November 2025, the DCGI directed state drug regulators to enforce revised GMP standards under Schedule M of the Drugs and Cosmetics Act, 1940, by January 2026. This initiative aims to align India's pharmaceutical manufacturing norms with global standards, enhancing the quality and safety of pharmaceutical exports.

In January 2022, Lebanon enacted the Lebanese Drug Agency (LDA) law (253/2022), establishing the LDA as the highest authority in the pharmaceutical sector. The LDA operates in coordination with the MOPH and other stakeholders to oversee the registration and regulation of pharmaceutical products.

These developments underscore the importance of compliance with updated GMP standards and regulatory frameworks for Indian pharmaceutical exporters aiming to access the Lebanese market.

In 2024, Lebanon's pharmaceutical imports totaled $737 million, with the United States accounting for $87 million. Local production contributed approximately $150 million, focusing mainly on manufacturing drugs under license for international companies. This indicates that about 70% of pharmaceutical products are imported, while 30% are produced domestically.

Acetylsalicylic formulations, commonly known as aspirin, are widely used in Lebanon for their analgesic, anti-inflammatory, and antipyretic properties. The demand is driven by the prevalence of cardiovascular diseases, an aging population, and increased healthcare awareness. While specific market size data for Acetylsalicylic formulations in Lebanon is not readily available, the significant importation of pharmaceutical products suggests a substantial demand for such medications.

Lebanon imposes a 0% MFN import duty on pharmaceutical products classified under HS code 30049099. Additionally, goods from European countries are exempt from customs fees under the European Mediterranean Association Agreement and the European Free Trade Association (EFTA) agreement, effective March 1, 2015. Similarly, goods from several Arab countries benefit from exemptions under the Greater Arab Free Trade Area (GAFTA) Agreement.

There is no Free Trade Agreement (FTA) between India and Lebanon that affects pharmaceutical tariffs. Consequently, Indian pharmaceutical exports to Lebanon are subject to the standard 0% MFN import duty. There are no reported anti-dumping duties or additional charges specifically targeting pharmaceutical imports from India.

In 2024, Lebanon imported pharmaceutical products worth $737 million, with the United States being the largest supplier, accounting for 11.8% of total imports. Other significant suppliers included Germany (11.66%), France (8.95%), and Switzerland (7.19%).

India's share in Lebanon's total Acetylsalicylic formulation imports is relatively modest. In 2025, India exported finished pharmaceutical formulations containing Acetylsalicylic worth $0.1 million to Lebanon, representing 2.7% of India's total Acetylsalicylic formulation exports, which amounted to $4.4 million.

Pricing comparisons between Indian Acetylsalicylic formulations and those from competitors like China and European manufacturers are not explicitly detailed in the available data. However, India's pharmaceutical industry is known for its cost-effective production capabilities, which often result in competitive pricing in international markets.

India is a leading global supplier of generic pharmaceuticals, accounting for approximately 20% of the world's generic medicine supply by volume as of 2024. The country's pharmaceutical industry is valued at over $50 billion, with exports exceeding $25 billion in the fiscal year 2022–23.

The nation boasts a robust manufacturing infrastructure, with over 650 U.S. FDA-approved facilities operating within its borders. This extensive network enables large-scale production of finished dosage forms, including tablets, capsules, and syrups containing acetylsalicylic acid.

India's cost-effective production capabilities are bolstered by a skilled workforce and favorable regulatory environments. The country has surpassed the United States in the number of FDA-registered generic manufacturing sites, with 752 FDA-approved, 2,050 WHO GMP-certified, and 286 EDQM-approved plants as of 2024.

India's pharmaceutical exports have been growing at 9%, nearly twice the global average, indicating a strong position in the global market.

Indian pharmaceutical companies supply nearly half of all generic prescriptions by volume in the United States, reflecting a strong track record of supply reliability.

India's pharmaceutical industry is the world's third-largest by volume and twelfth-largest by value, producing over 60,000 generic drugs in 60 therapeutic categories.

The country has over 650 U.S. FDA-approved manufacturing facilities, ensuring compliance with international quality standards.

India's pharmaceutical exports have been growing at 9%, nearly twice the global average, indicating a strong position in the global market.

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of acetylsalicylic formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish clear payment terms, such as letters of credit or advance payments, to build trust and ensure timely transactions with Indian suppliers.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet international quality standards and regulatory requirements.

• Regulatory Compliance: Verify that the selected suppliers have the necessary certifications, such as WHO-GMP and U.S. FDA approvals, to ensure product quality and facilitate smooth importation into Lebanon.

By meticulously following these guidelines, Lebanese companies can establish reliable partnerships with Indian suppliers, ensuring the consistent quality and regulatory compliance of Acetylsalicylic Acid formulations imported into Lebanon.